Gas6 and the receptor tyrosine kinase Axl in clear cell renal cell carcinoma

PLoS ONE

Volumn 4, Issue 10, 2009, Pages

  Gustafsson, Anna ^a   Boström, Anna Karin ^b   Ljungberg, Börje ^c   Axelson, Håkan ^b   Dahlbäck, Björn ^a  

^a University Hospital Malmö   (Sweden)

^b Malmö University Hospital   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH ARREST SPECIFIC PROTEIN 6; MESSENGER RNA; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE AXL; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; AXL RECEPTOR TYROSINE KINASE; GROWTH ARREST-SPECIFIC PROTEIN 6; ONCOPROTEIN; RECOMBINANT PROTEIN; SIGNAL PEPTIDE;

ARTICLE; CELL MIGRATION; CELL VIABILITY; CLEAR CELL CARCINOMA; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; LIGAND BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; BIOPSY; CELL MOTION; CELL SURVIVAL; CHEMISTRY; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

BIOPSY; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY NEOPLASMS; ONCOGENE PROTEINS; PHOSPHORYLATION; RECEPTOR PROTEIN-TYROSINE KINASES; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION;

EID: 70449449665     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007575     Document Type: Article

References (54)

1. Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103: 211-25.
2. Robinson DR, Wu YM, Lin SF (2000) The protein tyrosine kinase family of the human genome. Oncogene 19: 5548-57.
3. Hafizi S, Dahlback B (2006) Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine Growth Factor Rev 17: 295-304.
4. Linger RM, Keating AK, Earp HS, Graham DK (2008) TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res 100: 35-83.
5. Hafizi S, Dahlback B (2006) Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. Febs J 273: 5231-44.
6. Bellido-Martin L, de Frutos PG (2008) Vitamin K-dependent actions of Gas6. Vitam Horm 78: 185-209.
7. Manfioletti G, Brancolini C, Avanzi G, Schneider C (1993) The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol Cell Biol 13: 4976-85.
8. Angelillo-Scherrer A, de Frutos P, Aparicio C, Melis E, Savi P, et al. (2001) Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med 7: 215-21.
9. Evenas P, Garcia de Frutos P, Nicolaes GA, Dahlback B (2000) The second laminin G-type domain of protein S is indispensable for expression of full cofactor activity in activated protein C-catalysed inactivation of factor Va and factor VIIIa. Thromb Haemost 84: 271-7.
10. Goruppi S, Ruaro E, Schneider C (1996) Gas6, the ligand of Axl tyrosine kinase receptor, has mitogenic and survival activities for serum starved NIH3T3 fibroblasts. Oncogene 12: 471-80.
11. O'Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, et al. (1991) axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 11: 5016-31.
12. Janssen JW, Schulz AS, Steenvoorden AC, Schmidberger M, Strehl S, et al. (1991) A novel putative tyrosine kinase receptor with oncogenic potential. Oncogene 6: 2113-20.
13. Craven RJ, Xu LH, Weiner TM, Fridell YW, Dent GA, et al. (1995) Receptor tyrosine kinases expressed in metastatic colon cancer. Int J Cancer 60: 791-7.
14. Berclaz G, Altermatt HJ, Rohrbach V, Kieffer I, Dreher E, et al. (2001) Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast. Ann Oncol 12: 819-24.
15. Hutterer M, Knyazev P, Abate A, Reschke M, Maier H, et al. (2008) Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin Cancer Res 14: 130-8.
16. Ito T, Ito M, Naito S, Ohtsuru A, Nagayama Y, et al. (1999) Expression of the Axl receptor tyrosine kinase in human thyroid carcinoma. Thyroid 9: 563-7.
17. Sawabu T, Seno H, Kawashima T, Fukuda A, Uenoyama Y, et al. (2007) Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway. Mol Carcinog 46: 155-64.
18. Quong RY, Bickford ST, Ing YL, Terman B, Herlyn M, et al. (1994) Protein kinases in normal and transformed melanocytes. Melanoma Res 4: 313-9.
19. Shieh YS, Lai CY, Kao YR, Shiah SG, Chu YW, et al. (2005) Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia 7: 1058-64.
20. Gustafsson A, Martuszewska D, Johansson M, Ekman C, Hafizi S, et al. (2009) Differential Expression of Axl and Gas6 in Renal Cell Carcinoma Reflecting Tumor Advancement and Survival. Clin Cancer Res 15.
21. Vajkoczy P, Knyazev P, Kunkel A, Capelle HH, Behrndt S, et al. (2006) Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci U S A 103: 5799-804.
22. Holland SJ, Powell MJ, Franci C, Chan EW, Friera AM, et al. (2005) Multiple roles for the receptor tyrosine kinase axl in tumor formation. Cancer Res 65: 9294-303.
23. Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PF, et al. (2007) Renal cell carcinoma guideline. Eur Urol 51: 1502-10.
24. Cohen HT, McGovern FJ (2005) Renal-cell carcinoma. N Engl J Med 353: 2477-90.
25. Fiebeler A, Park JK, Muller DN, Lindschau C, Mengel M, et al. (2004) Growth arrest specific protein 6/Axl signaling in human inflammatory renal diseases. Am J Kidney Dis 43: 286-95.
26. Arai H, Nagai K, Doi T (2008) Role of growth arrest-specific gene 6 in diabetic nephropathy. Vitam Horm 78: 375-92.
27. Nagai K, Matsubara T, Mima A, Sumi E, Kanamori H, et al. (2005) Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy. Kidney Int 68: 552-61.
28. Yanagita M, Arai H, Ishii K, Nakano T, Ohashi K, et al. (2001) Gas6 regulates mesangial cell proliferation through Axl in experimental glomerulonephritis. Am J Pathol 158: 1423-32.
29. Yanagita M, Ishimoto Y, Arai H, Nagai K, Ito T, et al. (2002) Essential role of Gas6 for glomerular injury in nephrotoxic nephritis. J Clin Invest 110: 239-46.
30. Varnum BC, Young C, Elliott G, Garcia A, Bartley TD, et al. (1995) Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature 373: 623-6.
31. O'Bryan JP, Fridell YW, Koski R, Varnum B, Liu ET (1995) The transforming receptor tyrosine kinase, Axl, is post-translationally regulated by proteolytic cleavage. J Biol Chem 270: 551-7.
32. Hasanbasic I, Rajotte I, Blostein M (2005) The role of gamma-carboxylation in the anti-apoptotic function of gas6. J Thromb Haemost 3: 2790-7.
33. Tai KY, Shieh YS, Lee CS, Shiah SG, Wu CW (2008) Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-kappaB and Brg-1. Oncogene 27: 4044-55.
34. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, et al. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-5.
35. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC (2003) Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 23: 9361-74.
36. Fogh J (1978) Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors. Natl Cancer Inst Monogr. pp 5-9.
37. Sun W, Fujimoto J, Tamaya T (2004) Coexpression of Gas6/Axl in human ovarian cancers. Oncology 66: 450-7.
38. Zhang YX, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, et al. (2008) AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res 68: 1905-15.
39. Mc Cormack O, Chung WY, Fitzpatrick P, Cooke F, Flynn B, et al. (2008) Growth arrest-specific gene 6 expression in human breast cancer. Br J Cancer 98: 1141-6.
40. Fridell YW, Villa J, Jr., Attar EC, Liu ET (1998) GAS6 induces Axl-mediated chemotaxis of vascular smooth muscle cells. J Biol Chem 273: 7123-6.
41. Allen MP, Linseman DA, Udo H, Xu M, Schaack JB, et al. (2002) Novel mechanism for gonadotropin-releasing hormone neuronal migration involving Gas6/Ark signaling to p38 mitogen-activated protein kinase. Mol Cell Biol 22: 599-613.
42. Nielsen-Preiss SM, Allen MP, Xu M, Linseman DA, Pawlowski JE, et al. (2007) Adhesion-related kinase induction of migration requires phosphatidylinositol-3-kinase and ras stimulation of rac activity in immortalized gonadotropin-releasing hormone neuronal cells. Endocrinology 148: 2806-14.
43. Nagai K, Arai H, Yanagita M, Matsubara T, Kanamori H, et al. (2003) Growth arrest-specific gene 6 is involved in glomerular hypertrophy in the early stage of diabetic nephropathy. J Biol Chem 278: 18229-34.
44. Gallicchio M, Mitola S, Valdembri D, Fantozzi R, Varnum B, et al. (2005) Inhibition of vascular endothelial growth factor receptor 2-mediated endothelial cell activation by Axl tyrosine kinase receptor. Blood 105: 1970-6.
45. Bellosta P, Costa M, Lin DA, Basilico C (1995) The receptor tyrosine kinase ARK mediates cell aggregation by homophilic binding. Mol Cell Biol 15: 614-25.
46. Wimmel A, Glitz D, Kraus A, Roeder J, Schuermann M (2001) Axl receptor tyrosine kinase expression in human lung cancer cell lines correlates with cellular adhesion. Eur J Cancer 37: 2264-74.
47. Budagian V, Bulanova E, Orinska Z, Thon L, Mamat U, et al. (2005) A promiscuous liaison between IL-15 receptor and Axl receptor tyrosine kinase in cell death control. Embo J 24: 4260-70.
48. Williams RD, Elliott AY, Stein N, Fraley EE (1978) In vitro cultivation of human renal cell cancer. II. Characterization of cell lines. In Vitro 14: 779-86.
49. Iliopoulos O, Kibel A, Gray S, Kaelin WG, Jr. (1995) Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1: 822-6.
50. Ebert T, Bander NH, Finstad CL, Ramsawak RD, Old LJ (1990) Establishment and characterization of human renal cancer and normal kidney cell lines. Cancer Res 50: 5531-6.
51. Stenhoff J, Dahlback B, Hafizi S (2004) Vitamin K-dependent Gas6 activates ERK kinase and stimulates growth of cardiac fibroblasts. Biochem Biophys Res Commun 319: 871-8.
52. Brown MA, Stenberg LM, Persson U, Stenflo J (2000) Identification and purification of vitamin K-dependent proteins and peptides with monoclonal antibodies specific for gamma -carboxyglutamyl (Gla) residues. J Biol Chem 275: 19795-802.
53. Sobin LH, Wittekind C, eds. International Union Against Cancer (UICC). TNM Classification of Malignant Tumours. 6 ed. 2002, New York: Wiley-Liss. 193-5.
54. Skinner DG, Colvin RB, Vermillion CD, Pfister RC, Leadbetter WF (1971) Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer 28: 1165-77.